Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley Lipkowitz

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Research Square|December 3, 2025
Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor VenetoclaxSabrina C D Daglish, Owen G Canterbury, Paul R Graves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2022
Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical TrialDaniel S Green, Franklin Ning, Anna Duemler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2023
Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical TrialDaniel S Green, Franklin Ning, Anna Duemler, et al.
Redox Biology|November 14, 2022
Systemic Nos2 Depletion and Cox inhibition limits TNBC disease progression and alters lymphoid cell spatial orientation and densityVeena Somasundaram, Lisa A Ridnour, Robert Ys Cheng, et al.
JCI Insight|July 15, 2025
Elevated tumor NOS2/COX2 promotes immunosuppressive phenotypes associated with poor survival in ER- breast cancerLisa A Ridnour, Robert Ys Cheng, William F Heinz, et al.
Med (New York, N.Y.)|December 13, 2022
Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptomeGal Dinstag, Eldad D Shulman, Efrat Elis, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patientsLisa A Ridnour, Robert Y S Cheng, William F Heinz, et al.
Cell Death & Disease|June 29, 2026
Small molecule activators of the mitochondrial protease ClpP induce senescence in triple-negative breast cancer cells and sensitize cells to the Bcl-2 inhibitor venetoclaxSabrina C D Daglish, Owen G Canterbury, Paul R Graves, et al.
Cancer Research Communications|October 2, 2024
Tumor NOS2 and COX2 Spatial Juxtaposition with CD8+ T Cells Promote Metastatic and Cancer Stem Cell Niches that Lead to Poor Outcome in ER- Breast CancerLisa A Ridnour, William F Heinz, Robert Y S Cheng, et al.
JCI Insight|June 24, 2024
Adjuvant COX inhibition augments STING signaling and cytolytic T cell infiltration in irradiated 4T1 tumorsLisa A Ridnour, Robert Ys Cheng, Noemi Kedei, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Research Square|December 3, 2025
Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor VenetoclaxSabrina C D Daglish, Owen G Canterbury, Paul R Graves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2022
Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical TrialDaniel S Green, Franklin Ning, Anna Duemler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2023
Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical TrialDaniel S Green, Franklin Ning, Anna Duemler, et al.
Redox Biology|November 14, 2022
Systemic Nos2 Depletion and Cox inhibition limits TNBC disease progression and alters lymphoid cell spatial orientation and densityVeena Somasundaram, Lisa A Ridnour, Robert Ys Cheng, et al.
JCI Insight|July 15, 2025
Elevated tumor NOS2/COX2 promotes immunosuppressive phenotypes associated with poor survival in ER- breast cancerLisa A Ridnour, Robert Ys Cheng, William F Heinz, et al.
Med (New York, N.Y.)|December 13, 2022
Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptomeGal Dinstag, Eldad D Shulman, Efrat Elis, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patientsLisa A Ridnour, Robert Y S Cheng, William F Heinz, et al.
Cell Death & Disease|June 29, 2026
Small molecule activators of the mitochondrial protease ClpP induce senescence in triple-negative breast cancer cells and sensitize cells to the Bcl-2 inhibitor venetoclaxSabrina C D Daglish, Owen G Canterbury, Paul R Graves, et al.
Cancer Research Communications|October 2, 2024
Tumor NOS2 and COX2 Spatial Juxtaposition with CD8+ T Cells Promote Metastatic and Cancer Stem Cell Niches that Lead to Poor Outcome in ER- Breast CancerLisa A Ridnour, William F Heinz, Robert Y S Cheng, et al.
JCI Insight|June 24, 2024
Adjuvant COX inhibition augments STING signaling and cytolytic T cell infiltration in irradiated 4T1 tumorsLisa A Ridnour, Robert Ys Cheng, Noemi Kedei, et al.
Pageof 11